Your browser is no longer supported. Please, upgrade your browser.
ASMB Assembly Biosciences, Inc. daily Stock Chart
Assembly Biosciences, Inc.
Index- P/E- EPS (ttm)-3.42 Insider Own1.50% Shs Outstand35.08M Perf Week-0.30%
Market Cap772.57M Forward P/E- EPS next Y-3.74 Insider Trans-1.77% Shs Float30.43M Perf Month12.36%
Income-97.20M PEG- EPS next Q-0.32 Inst Own90.40% Short Float11.97% Perf Quarter46.78%
Sales16.20M P/S47.69 EPS this Y6.60% Inst Trans0.17% Short Ratio17.41 Perf Half Y13.75%
Book/sh7.18 P/B3.20 EPS next Y-39.00% ROA-34.80% Target Price- Perf Year71.90%
Cash/sh7.42 P/C3.10 EPS next 5Y17.00% ROE-45.40% 52W Range8.13 - 25.45 Perf YTD12.41%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-37.30% 52W High-9.63% Beta1.34
Dividend %- Quick Ratio12.10 Sales past 5Y- Gross Margin- 52W Low182.90% ATR1.39
Employees120 Current Ratio12.10 Sales Q/Q5.10% Oper. Margin- RSI (14)54.06 Volatility5.79% 6.51%
OptionableYes Debt/Eq0.00 EPS Q/Q27.90% Profit Margin- Rel Volume0.93 Prev Close23.02
ShortableYes LT Debt/Eq0.00 EarningsJun 03 AMC Payout- Avg Volume209.09K Price23.00
Recom1.20 SMA200.38% SMA509.35% SMA20030.56% Volume195,656 Change-0.09%
Oct-16-19Initiated Mizuho Buy $20
Nov-19-18Initiated Leerink Partners Outperform $45
Oct-08-18Upgrade B. Riley FBR Neutral → Buy $42
Aug-08-18Initiated Robert W. Baird Outperform $74
Apr-13-18Downgrade Chardan Capital Markets Buy → Neutral $35 → $50
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $35
Nov-08-17Initiated Jefferies Buy $50
May-30-17Initiated Chardan Capital Markets Buy $35
Jul-09-20 08:00AM  
Jul-02-20 04:30PM  
Jun-25-20 08:00AM  
Jun-24-20 08:55AM  
Jun-23-20 11:42AM  
Jun-22-20 08:45AM  
Jun-19-20 07:41AM  
Jun-18-20 04:01PM  
Jun-01-20 04:18PM  
May-27-20 08:00AM  
May-26-20 08:00AM  
May-19-20 04:05PM  
May-15-20 11:14AM  
May-13-20 10:58AM  
May-07-20 04:05PM  
May-06-20 06:33AM  
May-04-20 08:00AM  
May-01-20 05:00PM  
Apr-30-20 04:05PM  
Apr-06-20 08:00AM  
Mar-31-20 04:05PM  
Mar-30-20 08:00AM  
Mar-04-20 06:05PM  
Feb-20-20 12:31PM  
Feb-19-20 08:00AM  
Jan-28-20 06:00AM  
Dec-16-19 04:05PM  
Dec-12-19 06:30AM  
Dec-11-19 04:03PM  
Dec-10-19 11:11AM  
Dec-06-19 08:00AM  
Nov-18-19 08:00AM  
Nov-11-19 08:00AM  
Nov-08-19 04:13PM  
Nov-07-19 05:30PM  
Nov-06-19 04:40PM  
Oct-31-19 10:47AM  
Oct-30-19 06:58AM  
Oct-28-19 05:15PM  
Oct-18-19 11:02AM  
Oct-17-19 04:27PM  
Oct-16-19 07:05AM  
Sep-23-19 08:14AM  
Sep-15-19 09:16AM  
Aug-09-19 04:30PM  
Aug-07-19 08:00AM  
Aug-05-19 07:25PM  
Jul-17-19 01:08PM  
Jun-27-19 07:05AM  
Jun-25-19 04:05PM  
Jun-21-19 07:05AM  
Jun-14-19 04:41PM  
May-21-19 03:30PM  
May-09-19 07:45PM  
May-03-19 07:49AM  
Apr-29-19 10:31AM  
Apr-22-19 04:51PM  
Apr-15-19 01:37PM  
Apr-13-19 12:00PM  
Apr-11-19 07:05AM  
Apr-02-19 07:07AM  
Mar-27-19 07:05AM  
Mar-13-19 07:05AM  
Mar-06-19 01:35PM  
Feb-28-19 05:00PM  
Feb-19-19 05:47PM  
Feb-13-19 08:25AM  
Jan-31-19 09:30AM  
Jan-15-19 12:24PM  
Jan-07-19 07:00AM  
Dec-16-18 09:04AM  
Dec-03-18 08:52AM  
Nov-30-18 08:17AM  
Nov-12-18 07:05AM  
Nov-08-18 11:10AM  
Oct-31-18 10:32AM  
Oct-16-18 07:36AM  
Oct-08-18 03:16PM  
Oct-02-18 07:05AM  
Oct-01-18 08:43AM  
Aug-28-18 07:05AM  
Aug-16-18 07:35AM  
Aug-08-18 08:25PM  
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Colonno Richard JamesEVP & CSO, Virology OpsMar 31Sale15.047,812117,524137,009Mar 31 04:15 PM
Papkoff Jacqueline SybilSVP-CSO MicrobiomeMar 30Sale14.221,25417,83138,661Mar 31 04:16 PM
Papkoff Jacqueline SybilSVP-CSO MicrobiomeDec 13Sale21.001,46030,66222,915Dec 16 05:21 PM
Colonno Richard JamesEVP & CSO, Virology OpsDec 12Option Exercise7.0333,061232,419160,882Dec 16 05:17 PM
Colonno Richard JamesEVP & CSO, Virology OpsDec 12Sale25.0033,061826,578127,821Dec 16 05:17 PM